Found: 15
Select item for more details and to access through your institution.
Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 9, p. 1547, doi. 10.1093/neuonc/noab088
- By:
- Publication type:
- Article
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 8, p. 1039, doi. 10.1093/neuonc/noz088
- By:
- Publication type:
- Article
Radiologic progression of glioblastoma under therapy--an exploratory analysis of AVAglio.
- Published in:
- Neuro-Oncology, 2018, v. 20, n. 4, p. 557, doi. 10.1093/neuonc/nox162
- By:
- Publication type:
- Article
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 10, p. 1434, doi. 10.1093/neuonc/now091
- By:
- Publication type:
- Article
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 9, p. 1313, doi. 10.1093/neuonc/now046
- By:
- Publication type:
- Article
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 7, p. 991, doi. 10.1093/neuonc/nov300
- By:
- Publication type:
- Article
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
- Published in:
- Neuro-Oncology, 2015, v. 17, n. 7, p. 1007, doi. 10.1093/neuonc/nov019
- By:
- Publication type:
- Article
ASSOCIATION OF MATRIX METALLOPROTEINASE 2 (MMP2) BASELINE PLASMA LEVEL WITH RESPONSE AND SURVIVAL AND CHANGE OVERTIME IN PATIENTS TREATED WITH BEVACIZUMAB FOR RECURRENT HIGH GRADE GLIOMA.
- Published in:
- Neuro-Oncology, 2014, v. 16, n. suppl_3, p. iii48, doi. 10.1093/neuonc/nou209.23
- By:
- Publication type:
- Article
Author reply.
- Published in:
- Cancer (0008543X), 2004, v. 101, n. 12, p. 2898, doi. 10.1002/cncr.20708
- By:
- Publication type:
- Article
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 10, p. 2208
- By:
- Publication type:
- Article
Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population.
- Published in:
- Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00426
- By:
- Publication type:
- Article
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
- Published in:
- Acta Neuropathologica, 2021, v. 141, n. 6, p. 945, doi. 10.1007/s00401-021-02291-6
- By:
- Publication type:
- Article
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
- Published in:
- Oncologist, 2018, v. 23, n. 5, p. 524, doi. 10.1634/theoncologist.2017-0689
- By:
- Publication type:
- Article